肝硬化患者血清β_2M放免测定的临床意义

CLINICAL SIGNIFICANCES OF RADIOIMMUNOASSAY OF SERUM β_2-M IN PATIENTS WITH CIRRHOSIS

本文用放射免疫法测定了肝硬化30例的血清β_2微球蛋白(β_2M)含量,结果表明其浓度明显高于正常对照组。在肝硬化合并腹水中,随腹水量的增大,血清β_3M浓度渐增高。肝硬化并发原发性肝癌、肝性脑病组与无并发症组比较,血清β_2M升高明显(P<0.05)。肝功能Child分级A级与B级组间比较β_2M无显著差异(P>0.05),C级组较A、B级组β_2M增高明显(P<0.05)。本文建议动态观察血清β_2M的变化,以监测肝病活动程度、病情进展,并可作为肝癌的辅助诊断指标之一。

The serum β2-microglobulin(β2-M) in patients with liver cirrhosis were measured by radioim-munoassay. The results showed that the serum volume of β-Min patients with liver cirrhosis was significantly higher than that of healthy subjects. In hepatic cirrhosis with ascites,the serum level of β2-M was gradually increased with the increase in the volume of ascites. Significance difference between the groups accompanied by primary hepatic carcinoma and hepatic encephalopathy was noted in serum level of β2-M (P <0. 05) as compared with the group not accompanied. The serum volum of β2-M in hepatic function Child A was not different from that of Child B ( P > 0. 05),but for Child C it was significantly higher than that of Child A,and Child B( P <0. 05). It is suggested that changes in the serum of volume of β2-M should be actively observated to moniter hepatic disease activity and disease development,and they may be used as one of criteria to the adjutant diagnosis of hepatic carcinoma.